Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease

International Journal of Cardiology

Volumn 102, Issue 3, 2005, Pages 477-485

  Schlitt, Axel ^a   Blankenberg, Stefan ^a   Bickel, Christoph ^a   Meyer, Juergen ^a   Hafner, Gerd ^a   Jiang, Xian Cheng ^b   Rupprecht, Hans J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein A I; Coronary artery disease; Inflammation; Lipoproteins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AUTACOID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FATALITY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 21844447152     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.05.056     Document Type: Article

References (52)

1. G.J. Miller, and N.E. Miller Plasma-high-density lipoprotein concentration and development of ischemic heart-disease Lancet 1 1979 16 19
2. T. Gordon, J.L. Probstfield, J.R. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15
3. A.R. Sharret, C.M. Ballantyne, S.A. Coady, G. Heiss, P.D. Sorlie, and D. Catellier Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 2001 1108 1113
4. W.E. Boden High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial Am. J. Cardiol. 86 2000 19L 22L
5. M.J. Stampfer, F.M. Sacks, S. Salvini, W.C. Willett, and C.H. Hennekens A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N. Engl. J. Med. 325 1991 373 381
6. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
7. H. Doi, K. Kugiyama, H. Oka, S. Sugiyama, N. Ogata, and S.I. Koide Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism Circulation 102 2000 670 676
8. C. Colome, J. Martinez-Gonzalez, F. Vidal, C. de Castellarnau, and L. Badimon Small oxidative changes in atherogenic LDL concentrations irreversibly regulate adhesiveness of human endothelial cells: effect of the lazaroid U74500A Atherosclerosis 149 2000 295 302
9. D. Steinberg Low density lipoprotein oxidation and its pathobiological significance J. Biol. Chem. 272 34 1997 20963 20966
10. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
11. L.L. Bausserman, D.N. Bernier, K.P. McAdam, and P.N. Herbert Serum amyloid A and high density lipoproteins during the acute phase response Eur. J. Clin. Investig. 18 1988 619 626
12. I. Hardardottir, S.T. Kunitake, A.H. Moser, W.T. Doerrler, J.H. Rapp, and C. Grunfeld Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters J. Clin. Invest. 94 1994 1304 1309
13. S. Rossner Further studies on serum lipoproteins in connective tissue diseases Atherosclerosis 31 1978 93 99
14. C. Baumberger, R.J. Ulevitch, and J.M. Dayer Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein Pathobiology 59 1991 378 383
15. A. Miyazaki, A.T. Rahim, T. Ohta, Y. Morino, and S. Horiuchi High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells Biochim. Biophys. Acta 1126 1992 73 80
16. G.W. Cockerill, K.A. Rye, J.R. Gamble, M.A. Vadas, and P.J. Barter High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler. Thromb. Vasc. Biol. 15 1995 1987 1994
17. B.J. Van Lenten, M. Navab, D. Shih, A.M. Fogelman, and A.J. Lusis The role of high-density lipoproteins in oxidation and inflammation Trends Cardiovasc. Med. 11 2001 155 161
18. W.H. Ettinger, V.K. Varma, M. Sorci-Thomas, J.S. Parks, R.C. Sigmon, and T.K. Smith Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells Arterioscler. Thromb. 14 1994 8 13
19. W.H. Ettinger, W.H. Sun, N. Binkley, E. Kouba, and W. Ershler Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys J. Gerontol. A Biol. Sci. Med. Sci. 50 1995 M137 M140
20. G. Lippi, V. Braga, S. Adami, and G. Guidi Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response Clin. Chim. Acta 271 1998 79 87
21. N. Hyka, J.M. Dayer, C. Modoux, T. Kohno, C.K. Edwards 3rd, and P. Roux-Lombard Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes Blood 97 2000 2381 2389
22. C.J. Furlaneto, F.P. Ribeiro, E. Hatanaka, G.M. Souza, M.A. Cassatella, and A. Campa Apolipoproteins A-I and A-II downregulate neutrophil functions Lipids 37 2002 925 928
23. P.K. Shah Plaque disruption and thrombosis: potential role of inflammation and infection Cardiol. Clin. 17 1999 271 281
24. S. Volpato, E. Palmieri, R. Fellin, and G. Zuliani Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalised elderly patients Gerontology 46 1 2000 22 27
25. T. Sampietro, M. Tuoni, M. Ferdeghini, A. Ciardi, P. Marraccini, and C. Prontera Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia Circulation 96 1997 1381 1385
26. A. Ble, E. Palmieri, S. Volpato, F. Costantini, R. Fellin, and G. Zuliani White blood cell count is associated with some features of metabolic syndrome in a very old population Nutr. Metab. Cardiovasc. Dis. 11 2001 221 226
27. M.M. Wurfel, S.T. Kunitake, H. Lichenstein, J.P. Kane, and S.D. Wright Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS J. Exp. Med. 180 1994 1025 1035
28. L.L. Bausserman, D.N. Bernier, K.P. McAdam, and P.N. Herbert Serum amyloid A and high density lipoproteins during the acute phase response Eur. J. Clin. Invest. 18 1988 619 626
29. H. Hosoai, N.R. Webb, J.M. Glick, U.J. Tietge, M.S. Purdom, and F.C. de Beer Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice J. Lipid Res. 40 1999 648 653
30. A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, and A.M. Fogelman Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein J. Clin. Invest. 96 1995 2882 2891
31. K.K. Hamilton, J. Zhao, and P.J. Sims Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9 J. Biol. Chem. 268 1993 3632 3638
32. H.M. Dansky, S.A. Charlton, C.B. Barlow, M. Tamminen, J.D. Smith, and J.S. Frank Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium J. Clin. Invest. 104 1999 31 39
33. A.S. Major, D.E. Dove, H. Ishiguro, Y.R. Su, A.M. Brown, and L. Liu Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice Arterioscler. Thromb. Vasc. Biol. 21 2001 1790 1795
34. R.R. Singaraja, C. Fievet, G. Castro, E.R. James, N. Hennuyer, and S.M. Clee Increased ABCA1 activity protects against atherosclerosis J. Clin. Invest. 110 2002 35 42
35. C. Joyce, L. Freeman, H.B. Brewer Jr., and S. Santamarina-Fojo Study of ABCA1 function in transgenic mice Arterioscler. Thromb. Vasc. Biol. 23 2003 965 971
36. N. Wang, D.L. Silver, P. Costet, and A.R. Tall Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1 J. Biol. Chem. 275 2000 33053 33058
37. K.A. Rye, and P.J. Barter Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I Arterioscler. Thromb. Vasc. Biol. 24 2003 1 8
38. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention Eur. Heart J. 19 1998 1434 1503
39. P.M. Ridker High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention Am. J. Cardiol. 92 2003 17K 22K
40. M. Haim, M. Benderly, D. Brunner, S. Behar, E. Graff, and H. Reicher-Reiss Elevated serum triglycerides levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry Circulation 100 1999 475 482
41. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS) Am. J. Cardiol. 76 1995 899 905
42. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
43. J.S. Skinner, M. Farrer, C.J. Albers, H.AW. Neil, and P.C. Adams High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery Heart 81 1999 488 494
44. I. Bolibar, A. von Eckardstein, G. Assmann, and S. Thompson Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities Thromb. Haemost. 84 2000 955 960
45. M. Miller, A. Seidler, A. Moalemi, and T.A. Pearson Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Study J. Am. Coll. Cardiol. 31 1998 1252 1257
46. M.C. Francis, and J.J. Frohlich Coronary artery disease in patients at low risk-apolipoprotein AI as an independent risk factor Atherosclerosis 155 2001 165 170
47. A. Zambon, J.E. Hokanson, B.G. Brown, and J.D. Brunzell Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL-density Circulation 95 1999 69 75
48. M.J. Stampfer, F.M. Sacks, S. Salvini, W.C. Willett, and C.H. Hennenkens A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N. Engl. J. Med. 325 1991 373 381
49. U. Lundstam, J. Herlitz, T. Karlsson, T. Linden, and O. Wiklund Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease J. Intern. Med. 251 2002 111 118
50. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
51. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N. Engl. J. Med. 335 1996 1001 1009
52. H.R. Superko Beyond LDL cholesterol reduction Circulation 94 1996 2351 2354